What is the name of acotinib/acalabrutinib, and are there other names?

Acalabrutinib/Acalabrutinib is a drug used to treat lymphoma, and its English name is "Acalabrutinib". In addition to this official name, it has several aliases, including acalabrutinib, acalabrutinib, etc. These names are widely used in the medical field and on the market to refer to the same drug.

Acotinib is a Bruton's tyrosine kinase (BTK) inhibitor and is a second-generation BTK inhibitor. It inhibits the activity of BTK and blocks the BCR signaling pathway, thereby inhibiting the growth and survival of malignant B-cell tumors. This drug has shown therapeutic effects in the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and other disease types, and has been approved for marketing by the US Food and Drug Administration (FDA) and the my country Food and Drug Administration.

In the market, the trade names of acotinib include"Calquence" and "Calquence". These trade names are often used to distinguish the same drug produced by different manufacturers, or to distinguish drugs in different dosage forms and strengths. In China, acotinib was approved for domestic marketing for the first time in May 2023. Its public retail price is more than 40,000 yuan per box, and the specification is 100mg*8 tablets*7 plates/box.

In addition to the above names, acotinib may also be referred to by other abbreviations or abbreviations in medical literature and research, such asACP-196. However, these names are usually only used in specific fields or contexts and may not be familiar to general patients and the public.

In short, Acalabrutinib/Acalabrutinib is an important lymphoma treatment drug. Its official name is "Acalabrutinib", and its aliases include acalabrutinib, acalabrutinib, etc. It also has multiple trade names on the market, such as "Concoqi" and "Calquence". The presence of these names helps to distinguish the same drug or drugs in different dosage forms and strengths produced by different manufacturers.